ScinoPharm Taiwan (stock code 1789), a company specializing in the development of highly complex active pharmaceutical ingredients (APIs) and injectable formulations, announced that for the first half of 2019, its consolidated revenue totaled NTD 1.39 billion, net profit after tax was NTD 0.136 billion, and after-tax earnings per share were NTD 0.17. The consolidated revenue dropped by 24.76% on a year-on-year basis.

ScinoPharm Taiwan (stock code 1789), a company specializing in the development and manufacture of active pharmaceutical ingredients (APIs) and injectable formulations, announced that its 2018 consolidated annual revenue was NTD 3.524 billion, consolidated after-tax net profit was NTD 443 million, and after-tax earnings per share was NTD 0.56. The revenue and profitability have increased slightly from the previous year.

ScinoPharm Taiwan, Ltd (TWSE: 1789), an active pharmaceutical ingredient (API) and formulation specialty company, announced unaudited financial results for its fiscal year 2017. The consolidated revenue was NT$3.516 billion (US$120 million), after-tax net profits were NT$ 422 million (US$14.4 million). The after-tax earnings per share was NT$0.53 (US$0.018).

ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of delafloxacin active pharmaceutical ingredient (“API”) for Melinta’s Baxdela™,

International Inc. (NYSE: BAX) and ScinoPharm Taiwan, Ltd. (TWSE: 1789) today announced a strategic partnership to develop, manufacture and commercialize five injectable drugs used in a range of cancer treatments,